CUE
Cue Biopharma, Inc.
$33.39
+0.90 (+2.75%)
At close · Jul 7
Market Cap
$135.09M
Shares
4,045,701
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$33.39
Open$32.87
Day$30.07–33.75
52W$4.98–41.42
Avg vol 30d86K
Short int275K · 6.8% float · 3.7d
Short vol44%
Last earningsMar 16, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+93% above
+
Price vs 50-day avg
+28% above
◦
RSI (14)
61 · neutral
+
MACD trend
positive
◦
52-week position
78% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $26 › 200d $17 — 50d above 200d
+
Institutional flow
+15% holders QoQ · +15 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
6.80% of float · ▼ -1.0% MoM · 3.7 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
55 holders — mid 3-yr range
Fundamentals
Strong
+
Revenue growth
+196% Y/Y
+
EPS growth
+61% Y/Y
−
Free cash flow
$-21.9M
+
Balance sheet
net cash $23.1M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+93% above
Bullish
Price vs 50-day avg
+28% above
Bullish
RSI (14)
61 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
78% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $26 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.80% of float · ▼ -1.0% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $5
Now $33 · 78%
52-wk high $41
vs 200-day avg +93%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CUE
this stock
Cue Biopharma, Inc.
|
$135.09M | +264.9% | +195.7% | — | 6.8% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CUE | +9.7% | +13.3% | +222.6% | +5.8% | +264.9% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +8.8% | +12.0% | +215.1% | +5.7% | +255.3% |